Demonstrating Strength of Luye Pharma’s World-Leading Microspheres Technology Platform
The study has provided guidance to clinical medication for the treatment of advanced squamous cell lung carcin...
LY03005 is an exclusive CNS product developed under Luye Pharma’s New Chemical and Therapeutic Entities (NCE/...
Luye Pharma Group announced today that one of its key central nervous system (CNS) products, Rivastigmine Tran...
This regional initiative aims to raise mental health awareness, supporting patients, physicians and health sys...
Luye Pharma Group recently signed two agreements with partners in Latin America, boosting further development ...
TOP